

The ACRO Resident Committee has assembled the following resource sheet of resources we deemed most high yield. This is by no means an exhaustive list, and we welcome suggestions for additional resources/edits.

We hope this resource benefits your training and practice.

~ACRO Resident Education Subcommittee

General Resources

Many of these resources included disease site specific content. For the sake of brevity, these will not be repeated in the subsections.

1. Overview

National Comprehensive Cancer Network (NCCN):

<https://www.nccn.org/>

Very basic overview, great for staging and beginners

Essentials of Radiation Oncology (textbook for purchase):

Beginner level summaries

RADONC Talks:

https://www.youtube.com/@Rad_Onc_Talks

Excellent video series from one of our former committee members, excellent introduction for beginners

RadOncQuestions.com Question Bank:

<https://www.radoncquestions.com/>

Optimal for clinical boards study resource

ASTRO Refresher Course (purchase required):

<https://www.astro.org/meetings-and-education/micro-sites/2025/annual-refresher-course>

Highlights of the most important studies with emphasis on new data, great for all levels, must know for advanced residents

Estes RadOnc Tables Guides:

<https://radonctables.com/>

List and summaries of clinical studies you need to know (comprehensive), good basic level overview for beginners, comprehensive list is good for all residents

Rad Onc Review:

<https://www.radoncreview.org/>

The more advanced overview, for advanced level residents

ACRO YouTube Channel:

<https://www.youtube.com/channel/UCSzpY2tx6ujMHFghiC65a8g>

Ongoing resource for various topics, hosting continuing webinars live and recorded (see our website/social media for details)

Association of Residents in Radiation Oncology (ARRO) Resident Resources:

<https://www.astro.org/Affiliate/ARRO/Resident-Resources>

Radiation Oncology Education Collaborative Study group (ROECSCG) web resources:

<https://voices.uchicago.edu/roecsg/web-resources/study-materials/>

Radiation Oncology Virtual Education Rotation

<https://www.radoncvirtual.com/>

1MED:

<https://web.1medicine.app/>

Personalized education platform

2. Staying Up to Date Resources

QuadShot:

<http://www.quadshotnews.com/>

Regular email updates on new studies, great for all levels

The Mednet:

<https://www.themednet.org/>

Chat forum on unique cases/questions with expert input, reddit style forum

3. General Contouring and Planning Resources

eContour:

<https://econtour.org/>

Examples of common cases, good for beginners and new cases

EQD2 Calc:

<http://eqd2.com/>

AAPM TG 101 - SBRT constraints:

<https://www.aapm.org/pubs/reports/detail.asp?docid=102>

Meet me in Treatment Planning:

<https://www.astro.org/Affiliate/ARRO/ResidentResources/Educational-Resources/ASTRO-ARRO-Meet-Me-in-Treatment-Planning-Webinars>

Into to plan evaluation

4. Students Resources4.

Radiation Oncology: a Primer for Medical Students:

<https://www.ncbi.nlm.nih.gov/pubmed/23807599>

ROECSG Intro to Radiation Oncology:

<https://voices.uchicago.edu/roecsg/introduction-toradiation-oncology/>

Applying to Radiation Oncology:

<https://www.youtube.com/watch?v=faLDYAqABxg>

5. Patient Education

ACS:

<https://www.cancer.org/health-care-professionals/patient-education-materials-forprofessionals.html>

NCI:

<https://www.cancer.gov/publications/patient-education>

ASCO: <https://www.cancer.net/about-us/asco-answers-patient-education-materials/ascoanswers-fact-sheets>

6. Toxicity References

CTCAE v5.0 (Quick Reference PDF – 8.5 × 11):

<https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-8x11.pdf>

Official NCI/DCTD quick-reference for grading acute and late toxicities (Grades 1–5).

PRO-CTCAE (NCI):

<https://healthcaredelivery.cancer.gov/pro-ctcae/>

Patient-reported outcomes version of CTCAE. Click “Instruments & Form Builder” to download the item library or create custom surveys for skin, pain, fatigue, and arm symptoms.

CENTRAL NERVOUS SYSTEM (CNS)

1. Contouring & Planning

Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology (2021)
[https://www.thegreenjournal.com/article/S0167-8140\(21\)06251-4/fulltext](https://www.thegreenjournal.com/article/S0167-8140(21)06251-4/fulltext)

ESTRO ACROP guideline for target volume delineation of skull base tumors (2021)
[https://www.thegreenjournal.com/article/S0167-8140\(20\)31179-8/fulltext](https://www.thegreenjournal.com/article/S0167-8140(20)31179-8/fulltext)

2. Consensus Guidelines

ASTRO Clinical Practice Guideline – WHO Grade 4 Adult-Type Diffuse Glioma (2025)
[https://www.practicalradonc.org/article/S1879-8500\(25\)00163-8/fulltext](https://www.practicalradonc.org/article/S1879-8500(25)00163-8/fulltext)

ASTRO Clinical Practice Guideline – IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma (2022)
[https://www.practicalradonc.org/article/S1879-8500\(22\)00144-8/fulltext#relatedArticles](https://www.practicalradonc.org/article/S1879-8500(22)00144-8/fulltext#relatedArticles)

ASCO/ASTRO/SNO Guideline – Treatment of Brain Metastases (2021)
<https://ascopubs.org/doi/full/10.1200/JCO.21.02314>

ASTRO Clinical Practice Guideline – Brain Metastases (2022)
[https://www.practicalradonc.org/article/S1879-8500\(22\)00054-6/fulltext](https://www.practicalradonc.org/article/S1879-8500(22)00054-6/fulltext)

ISRS practice recommendations for non-functioning pituitary adenomas (2020): SRS is effective and safe.
<https://pubmed.ncbi.nlm.nih.gov/31790121/>

Carlson & Link – Vestibular Schwannomas (NEJM 2021): Overview of VS management; SRS dosing, tumor control, hearing preservation, facial nerve outcomes.
<https://www.nejm.org/doi/full/10.1056/NEJMra2020394>

Congress of Neurological Surgeons Guideline (2025): Single-fraction SRS recommended over hypo-fractionated SRS (2-5 fractions) as it results in decreased cranial nerve dysfunction.
<https://www.cns.org/guidelines/treatment-adults-vestibular-schwannoma/6-role-of-radiosurgery-srs-radiation-therapy-in-ma>

GYNECOLOGIC

1. Contouring and Planning

Consensus Guidelines for Delineation of Clinical Target Volumes for Intensity Modulated Radiation Therapy for Intact Cervical Cancer: An Update

[Consensus Guidelines for Delineation of Clinical Target Volumes for Intensity Modulated Radiation Therapy for Intact Cervical Cancer: An Update - PubMed](#)

Includes Variations and Challenging cases

EMBRACE II Contouring Protocol

<https://www.embracestudy.dk/UserUpload/PublicDocuments/EMBRACE%20II%20Protocol.pdf>

Brachytherapy Contouring Consensus

NRG/TOG Consensus Guidelines for Postop IMRT – Endometrial/Cervical (2020)

<https://pubmed.ncbi.nlm.nih.gov/32905846/>

Definitive RT with IGABT for primary vaginal cancer (2020)

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(19\)30855-1/abstract](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30855-1/abstract)

Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma (2016)

[https://www.redjournal.org/article/S0360-3016\(16\)00163-2/abstract](https://www.redjournal.org/article/S0360-3016(16)00163-2/abstract)

2. Consensus Guidelines

SGO/ASTRO/ABS: Minimum standards for RT for cervical cancer in the US (2025)

[https://www.gynecologiconcology-online.net/article/S0090-8258\(25\)00938-2/fulltext](https://www.gynecologiconcology-online.net/article/S0090-8258(25)00938-2/fulltext)

ABS: Hybrid intracavitary interstitial brachytherapy for LACC (2025)

[https://www.brachyjournal.com/article/S1538-4721\(25\)00086-8/abstract](https://www.brachyjournal.com/article/S1538-4721(25)00086-8/abstract)

ASTRO Clinical Practice Guideline – Cervical Cancer (2020)

[https://www.practicalradonc.org/article/S1879-8500\(20\)30094-1/fulltext](https://www.practicalradonc.org/article/S1879-8500(20)30094-1/fulltext)

ASTRO Clinical Practice Guideline – Endometrial Cancer (2023)

[https://www.practicalradonc.org/article/S1879-8500\(22\)00273-9/fulltext](https://www.practicalradonc.org/article/S1879-8500(22)00273-9/fulltext)

GROINSS-V II (JCO 2021): Inguinal RT is SOC for sentinel node micromets; avoids morbid lymphadenectomy.

<https://ascopubs.org/doi/10.1200/JCO.21.00006>

Protocol Establishes Guidance on Treatment of Nodal Regions

BREAST

1. Contouring & Planning

RADCOMP Breast Atlas:

<https://www.nrgoncology.org/About-Us/Center-for-Innovation-in-Radiation-Oncology/Breast-Cancer/RADCOMP-Breast-Atlas>

Most updated atlas for ENI.

NRG Oncology – Breast Atlases, Templates & Tools:

<https://www.nrgoncology.org/ciro-breast>

Portal with access to contouring atlases and planning templates (login may be required).

ESTRO-ACROP DIBH Implementation Guideline (2023):

<https://www.sciencedirect.com/science/article/pii/S0167814023002724>

Consensus on breath-hold implementation for cardiac sparing in left-sided and right-sided breast RT.

ESTRO-ACROP PMRT after Implant Reconstruction (2024):

<https://pubmed.ncbi.nlm.nih.gov/38846971/>

Technical guidance for PMRT in patients with implant-based reconstruction.

2. Guidelines / Consensus Statements

ASTRO Whole-Breast Irradiation Guideline:

<https://www.astro.org/provider-resources/guidelines/whole-breast-irradiation-gl>

Recommendations for fractionation, boost, and planning for WBI.

ASTRO Partial-Breast Irradiation Guideline (2024):

<https://www.astro.org/provider-resources/guidelines/clinical-practice-guidelines/pbi-guideline-replacement>

Updated indications and technique recommendations for PBI.

ESTRO Consensus on Target Volumes for Early Breast RT (Coles et al.):

[https://www.thegreenjournal.com/article/S0167-8140\(14\)00524-6/fulltext](https://www.thegreenjournal.com/article/S0167-8140(14)00524-6/fulltext)

European consensus on volume definitions for early-stage breast RT.

3. Toxicity / Quality of Life / Special Topics

Darby et al., Ischemic heart disease after breast RT (NEJM 2013):

<https://pubmed.ncbi.nlm.nih.gov/23484825/>

Every 1 Gy increase in mean heart dose raised major coronary events by ~7%; justifies DIBH and cardiac sparing.

Warren et al., Radiation and lymphedema risk (Ann Surg Oncol 2014):

<https://pmc.ncbi.nlm.nih.gov/articles/PMC3928974/>

Prospective cohort showing regional nodal RT and axillary surgery increase lymphedema risk; guides dose and volume counseling.

FAST-Forward QOL Extension (PMC 2024):

<https://pmc.ncbi.nlm.nih.gov/articles/PMC11017153/>

Confirmed 1-week ultra-hypofractionated WBI has similar late toxicity and cosmetic outcomes as 3-week regimens.

EORTC QLQ-C30 and BR23 (breast-specific):

<https://qol.eortc.org/questionnaires/>

Standard QoL tools for breast RT trials covering arm symptoms, breast symptoms, body image, and systemic therapy effects.

HEAD & NECK

1. Contouring & Planning

Lee & Lu – Target Volume Delineation and Field Setup (Head & Neck Planning Atlas):

<https://link.springer.com/book/10.1007/978-3-642-28860-9>

Gold-standard textbook for target delineation, field design, and planning nuances in conformal and IMRT for head and neck sites (Lee NY, Lu JJ eds., Springer 2012).

Radiopaedia LN levels

<https://radiopaedia.org/articles/lymph-node-levels-of-the-neck>

Good basic examples of all the lymph node levels

ESTRO-ACROP Guideline for Target Volume Delineation of Skull Base Tumors (Combs et al., Radiother Oncol 2021):

[https://www.thegreenjournal.com/article/S0167-8140\(20\)31179-8/fulltext](https://www.thegreenjournal.com/article/S0167-8140(20)31179-8/fulltext)

Consensus-based contouring atlas for skull-base tumors; defines GTV/CTV expansions near the clivus, Meckel's cave, cavernous sinus, and jugular foramen.

EORTC / Brouwer et al. CT-based delineation of organs at risk in the head and neck region (OAR atlas):

<https://www.eortc.org/app/uploads/2018/02/Atlas-HN.pdf>

Widely used OAR atlas for parotid, submandibular, pharyngeal constrictors, larynx, brachial plexus.

ESTRO-ACROP lymph-node delineation for H&N (elective nodal stations):

<https://www.sciencedirect.com/science/article/pii/S0167814021067219>

Standardizes levels I–VI and RPLN coverage for N0/N+ patients.

A contouring guide for head and neck cancers with perineural invasion

[A contouring guide for head and neck cancers with perineural invasion - PubMed](#)

2. Guidelines / Consensus Statements

ASTRO Clinical Guideline – Radiation therapy for HPV-positive oropharyngeal SCC (2024):

<https://pubmed.ncbi.nlm.nih.gov/39078350/>

Definitive and postoperative dose/volume guidance and de-escalation principles for HPV+ OPSCC.

ASTRO HPV+ guideline public page:

<https://www.astro.org/provider-resources/guidelines/clinical-practice-guidelines/hpv-positive-oropharyngeal-scc>

Public-facing page for residents.

4. Toxicity / Quality of Life / Special Topics

PARSPORT – IMRT reduces xerostomia vs conventional RT (Lancet Oncol 2011):

<https://pmc.ncbi.nlm.nih.gov/articles/PMC3033533/>

Randomized trial showing IMRT reduces xerostomia and improves QoL compared with 3D techniques.

EORTC QLQ-C30 + H&N35 QoL instruments:

<https://qol.eortc.org/questionnaires/>

Standardized QoL tools used in H&N trials for swallowing, speech, dry mouth, and social eating.

ORATOR – TORS vs (chemo)RT for HPV+ oropharynx:

<https://pubmed.ncbi.nlm.nih.gov/31416685/>

Useful for tumor boards comparing functional outcomes of surgery vs RT.

THORACIC

1. Contouring & Planning

EORTC contouring and treatment planning guidelines:

<https://pubmed.ncbi.nlm.nih.gov/28666551/>

Early Stage NSCLC

RTOG Atlas

<https://www.rtog.org/corelab/contouringatlas/lungatlas.aspx>

Advanced NSCLC

ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer:

<https://www.ncbi.nlm.nih.gov/pubmed/29605476>

Atlas of Mediastinal LN stations:

<https://pubmed.ncbi.nlm.nih.gov/16111586/>

2. Guidelines / Consensus Statements

ASTRO Guideline on Stereotactic Body Radiation Therapy (SBRT) for Early Stage Non-small Cell Lung Cancer (NSCLC):

<https://www.astro.org/provider-resources/guidelines/astro-s-guideline-on-sbrt-for-early-stage-nscle>

ASCO Stage III NSCLC Guideline (ASTRO-endorsed):

https://www.practicalradonc.org/article/S1879-8500%2823%2900005-X/fulltext?utm_source=chatgpt.com

ASTRO Clinical Practice Guideline (Small Cell Lung Cancer)

<https://pubmed.ncbi.nlm.nih.gov/32222430/>

ESMO Guideline (Small Cell Lung Cancer)

<https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Small-Cell-LungCancer>

3. Toxicity / Quality of Life / Special Topics

RTOG 0813. SBRT in medically inoperable central NSCLC (Table 3):

<https://www.ncbi.nlm.nih.gov/pubmed/30943123>

Recommended normal lung constraints:

<https://pubmed.ncbi.nlm.nih.gov/30496880/>

PEDIATRICS

PENTEC Guidelines

[https://www.redjournal.org/article/S0360-3016\(23\)07918-X/fulltext](https://www.redjournal.org/article/S0360-3016(23)07918-X/fulltext)

Dose constraints specific to Pediatrics

COG Website

<https://www.childrensoncologygroup.org/>

Children's Oncology Group- includes links to supportive care guidelines for patients

ACNS 1422

<https://pubmed.ncbi.nlm.nih.gov/34110925/>

Medulloblastoma contouring guide

AREN1921

<https://clinicaltrials.gov/study/NCT04322318>

Includes constraints for Wilms tumor- open protocol

ACNS 0121

<https://pubmed.ncbi.nlm.nih.gov/30811284/>

Set standard practice for radiation in ependymoma

ACNS 1123

<https://pubmed.ncbi.nlm.nih.gov/34850169/>

<https://pmc.ncbi.nlm.nih.gov/articles/PMC9645815/>

Sets standard practice for germinoma and nongerminoma- two arms

ANBL2131

<https://clinicaltrials.gov/study/NCT06172296>

Open protocol includes standard radiation practice for neuroblastoma

Proton therapy in pediatric and AYA non-rhabdomyosarcoma STS (Vennarini et al., 2024):

<https://pmc.ncbi.nlm.nih.gov/articles/PMC11083115/>

Demonstrates late-effect sparing and dosimetric advantages in pediatric/AYA STS.

Proton therapy to reduce late complications in pediatric sarcoma (Spiotto et al., Adv Radiat Oncol 2023):

<https://www.sciencedirect.com/science/article/pii/S2331518023001944>

Summarizes rationale for PBT to limit dose to growth plates, bowel, and fertility-critical structures.

HEMATOLOGIC

ILROG (International Lymphoma Radiation Oncology Group)

<https://www.ilrog.org/guidelines>

Extensive Library of Resources Regarding all Types of Lymphomas

Consensus Organ at Risk (OAR) Constraints for Radiotherapy (RT) for Hematologic Malignancies for NCTN Trials

<https://amportal.astro.org/sessions/qp-17-21599/consensus-organ-at-risk-oar-constraints-for-radiotherapy-rt-for-hematologic-malignancies-for-106726>

recently presented in abstract only at this time

ASTRO Refresher Lymphoma Contouring (2025)

<https://academy.astro.org/homepage>

Additional session dedicated to contouring

Children, Adolescent, Young Adult Hodgkin Lymphoma Consensus

<https://pubmed.ncbi.nlm.nih.gov/39835977/>

SARCOMA

1. Contouring & Planning

RTOG / Multi-institutional consensus on preoperative RT target volumes (Wang et al., IJROBP 2012):

<https://pubmed.ncbi.nlm.nih.gov/21676552/>

Defines GTV and CTV for high-grade extremity STS treated preoperatively; standardizes margins and contour variability.

Preoperative RT for extremity STS – practical review (Haas et al., Radiat Oncol 2015):

<https://pmc.ncbi.nlm.nih.gov/articles/PMC5506844/>

Open-access review summarizing timing, dose (50 Gy preop vs 60–66 Gy postop), and wound-complication considerations.

Retroperitoneal sarcoma RT – STRASS-era discussion (Bonvalot et al., Lancet Oncol 2020):

<https://pubmed.ncbi.nlm.nih.gov/32941794/>

Defines when and why preoperative RT is considered for RPS; use for field concept reference (see Key Trials).

Radiation Therapy in Adult STS – current knowledge and future directions (Roeder et al., Cancers 2020):

<https://www.mdpi.com/2072-6694/12/11/3242>

Comprehensive overview of RT indications, dose/fractionation, and OAR constraints in adult STS.

Agreement among sarcoma RT oncologists on target definition (Bahig et al., IJROBP 2013):

<https://pmc.ncbi.nlm.nih.gov/articles/PMC3646910/>

Highlights importance of standardized contouring to minimize marginal miss.

2. Guidelines / Consensus Statements

NCCN Soft Tissue Sarcoma Insights (update summary):

<https://pubmed.ncbi.nlm.nih.gov/35830886/>

Narrative overview of NCCN recommendations including RPS management updates.

4. Toxicity / Quality of Life / Wound Complications

Late-effect reduction per RTOG 0630: see Key Trials for link

Preop IGRT with smaller margins lowered late edema, joint stiffness, and fracture rates.

Preop RT for extremity STS – wound complication review (Haas et al., Radiat Oncol 2015):

<https://pmc.ncbi.nlm.nih.gov/articles/PMC5506844/>

Summarizes trade-off: higher acute wound risk but better late function and fibrosis profile.

5. Proton / Particle Therapy (Selected Indications)

ASTRO Model Policy – Proton Beam Therapy:

<https://www.astro.org/practice-support/reimbursement/model-policies>

Defines clinical scenarios for PBT coverage (pediatric tumors, skull-base sarcomas, and cases where photon plans cannot meet OAR constraints).

Proton RT for skull-base chordoma and chondrosarcoma (Hug et al., MGH series):

<https://pubmed.ncbi.nlm.nih.gov/11082173/>

Long-term results show durable local control with acceptable toxicity at 70 GyRBE for axial sarcomas.

GASTROINTESTINAL

Dr. Nina Sanford (UTSW) has excellent videos on YouTube covering GI malignancies.

<https://www.youtube.com/@NinaNSanfordMD>

ANORECTAL

1. Anatomy:

Deep dive video, “Rectal MRI: Intro to Expert, Rectal Cancer Staging”:

<https://www.youtube.com/watch?v=bp9rQv0BCIA&t=1s>

Deep dive paper, “Anorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation Therapy”:

<https://pmc.ncbi.nlm.nih.gov/articles/PMC4664281/>

Defines spread patterns, lymphatics, boundaries relevant to CTV contouring.

2. Contouring & Planning

Anorectal Contouring Atlas RTOG 0529

<https://pubmed.ncbi.nlm.nih.gov/19117696/>

Defines Volumes used in RTOG 0529

International Rectal Cancer CTV Consensus Guidelines (2016):

[https://www.thegreenjournal.com/article/S0167-8140\(16\)31213-0/fulltext](https://www.thegreenjournal.com/article/S0167-8140(16)31213-0/fulltext)

3. Society Guidelines

ESMO (2025):

<https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-localised-rectal-cancer>

ASTRO (2025):

[https://www.practicalradonc.org/article/S1879-8500\(24\)00304-7/fulltext](https://www.practicalradonc.org/article/S1879-8500(24)00304-7/fulltext)

ASCRS (2020):

[https://www.ascrsu.com/ascrs/view/ASCRS-](https://www.ascrsu.com/ascrs/view/ASCRS-Toolkit/2851064/all/Management_of_Rectal_Cancer_2020)

[Toolkit/2851064/all/Management_of_Rectal_Cancer_2020](https://www.ascrsu.com/ascrs/view/ASCRS-Toolkit/2851064/all/Management_of_Rectal_Cancer_2020)

This is a surgical guideline; this helps us align with surgical expectations and TME principles.

4. Quality of Life/Toxicity

RTOG 0822 IMRT GI tox (table 3):

<https://www.ncbi.nlm.nih.gov/pubmed/26163334>

IMRT did not reduce grade 2+ GI toxicity.

German Rectal Trial. Preop vs postop tox (table 5):

<https://www.ncbi.nlm.nih.gov/pubmed/15496622>

Postop CRT had much higher toxicity; i.e. don't delay CRT.

MRC CR07. Preop vs postop QOL:

<https://www.ncbi.nlm.nih.gov/pubmed/20585099>

Preop SCRT may affect sexual function and some aspects of bowel functioning, in combination with adverse effects from surgery.

ESOPHAGEAL and GASTRIC

1. Contouring & Planning

Contouring Atlas for Esophageal/GEJ Cancer (2013)

<https://www.sciencedirect.com/science/article/abs/pii/S036030161500351X>

Gastric Lymph Node Contouring Atlas (2012)

[https://www.practicalradonc.org/article/S1879-8500\(12\)00051-3/pdf](https://www.practicalradonc.org/article/S1879-8500(12)00051-3/pdf)

2. Consensus Guidelines

ASTRO Clinical Practice Guideline – Gastric Cancer (2025)

[https://www.practicalradonc.org/article/S1879-8500\(25\)00270-X/fulltext](https://www.practicalradonc.org/article/S1879-8500(25)00270-X/fulltext)

STS/ASTRO Clinical Practice Guideline – Esophageal Cancer (2024)

[https://www.practicalradonc.org/article/S1879-8500\(23\)00278-3/fulltext](https://www.practicalradonc.org/article/S1879-8500(23)00278-3/fulltext)

PANCREATIC

1. Contouring & Planning

Upper abdominal normal organ contouring guidelines/atlas (2014)

[https://www.practicalradonc.org/article/S1879-8500\(13\)00262-2/abstract](https://www.practicalradonc.org/article/S1879-8500(13)00262-2/abstract)

NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy

[https://www.redjournal.org/article/S0360-3016\(24\)03516-8/abstract](https://www.redjournal.org/article/S0360-3016(24)03516-8/abstract)

Contouring for MR-guided SBRT to Pancreas (*free for ASTRO Member-in-Training*)

<https://academy.astro.org/content/contouring-mr-guided-sbirt-pancreas#group-tabs-node-course-default4>

2. Consensus Guidelines

ASTRO Clinical Practice Guideline – Pancreatic Cancer (2019, *update in progress*)

<https://www.practicalradonc.org/cms/10.1016/j.prro.2019.06.016/attachment/0e8abbe7-fcc6-4c5d-8b46-e81e636ce080/mmc1.pdf>

HEPATOBIILIARY

ASTRO Clinical Practice Guideline – Primary Liver Cancer (2022)

[https://www.practicalradonc.org/article/S1879-8500\(21\)00233-2/fulltext](https://www.practicalradonc.org/article/S1879-8500(21)00233-2/fulltext)

ASTRO Refresher Upper GI Contouring (2025)

<https://academy.astro.org/homepage>

Additional session dedicated to contouring

GENITOURINARY

PROSTATE CANCER (INTACT)

1. Contouring & Planning

Combined RMH and RTOG guidelines:

<https://www.ncbi.nlm.nih.gov/pubmed/26104940>

RTOG atlas:

<https://www.rtog.org/CoreLab/ContouringAtlases/ProstatePelvicLymphNodes.aspx>

2. Guidelines / Consensus Statements

ASTRO guideline:

<https://www.astro.org/Patient-Care-and-Research/Clinical-PracticeStatements/ASTRO-39;s-evidence-based-guideline-on-clinically>

ASTRO/ASCO/AUA hypo-fractionation:

<https://www.ncbi.nlm.nih.gov/pubmed/30307776>

ABS guideline:

<https://www.americanbrachytherapy.org/consensus-statements/prostate/>

GEC/ESTRO HDR:

<https://www.ncbi.nlm.nih.gov/pubmed/23773409>

3. Toxicity / Quality of Life / Special Topics

ProtecT QoL AS vs RP vs RT:

<https://www.ncbi.nlm.nih.gov/pubmed/27626365>

PROST-QA trial:

<https://www.ncbi.nlm.nih.gov/pubmed/18354103/>

DART 01/05 short vs long term ADT:

<https://www.ncbi.nlm.nih.gov/pubmed/27598804>

ASCENDE-RT tox analysis:

<https://www.ncbi.nlm.nih.gov/pubmed/28433432>

PROSTATE CANCER (POST-PROSTATECTOMY / FOSSA)

RTOG consensus guidelines:

<https://www.ncbi.nlm.nih.gov/pubmed/19394158>

RTOG atlas:

<https://www.rtog.org/CoreLab/ContouringAtlases/ProstatePostOp.aspx>

ASTRO guideline:

<https://www.astro.org/Patient-Care-and-Research/Clinical-PracticeStatements/ASTRO-39;s-guideline-on-adjuvant-and-salvage-RT-af>

SAKK 09/10 standard vs high dose salvage RT:

<https://www.ncbi.nlm.nih.gov/pubmed/26527774>

German analysis RP only vs adj RT vs adj ADT vs adj RT + ADT:

<https://www.ncbi.nlm.nih.gov/pubmed/27887941>

Patient reported outcomes after postprostatectomy IMRT:

<https://pubmed.ncbi.nlm.nih.gov/31113644/>

BLADDER CANCER

1. Contouring & Planning

PORT: <https://www.ncbi.nlm.nih.gov/pubmed/27511849>

NRG Protocol Radiation Therapy Template (Bladder – Photon/Proton):

https://www.nrgoncology.org/wp-content/uploads/2025/09/RT-section-Protocol-BladderTreatment-Template-FINAL-09_24_2020_updated.pdf

CTV in MIBC:

<https://www.ncbi.nlm.nih.gov/pubmed/19394154>

2. Guidelines / Consensus Statements and Protocols

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline:

<https://www.ncbi.nlm.nih.gov/pubmed/28456635>

BC 2001. RT with/without chemo:

<https://www.birmingham.ac.uk/Documents/collegemds/trials/crcu/bc2001/Investigators/Trial-Protocol.pdf>

Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial

<https://pubmed.ncbi.nlm.nih.gov/39353477/>

3. Toxicity / Quality of Life / Special Topics

BC2001 acute toxicity (Table 2):

<https://www.ncbi.nlm.nih.gov/pubmed/22512481>

RTOG pooled analysis late toxicity:

<https://www.ncbi.nlm.nih.gov/pubmed/19636019>

QOL in bladder preservation review:

<https://www.ncbi.nlm.nih.gov/pubmed/26343030>

TESTICULAR CANCER

Target Volumes (Boujelbene 2011):

<https://pubmed.ncbi.nlm.nih.gov/21819630/>

RT planning for testicular seminoma:

[https://www.redjournal.org/article/S0360-3016\(12\)00096-X/fulltext](https://www.redjournal.org/article/S0360-3016(12)00096-X/fulltext)

SAKK 01/10 (30 Gy stage IIA, 36 Gy stage IIB): <https://pubmed.ncbi.nlm.nih.gov/36228644/>

MRCT TE 10:

<https://pubmed.ncbi.nlm.nih.gov/10561173/>

Contouring for Stage I

MRC TE 18:

<https://pubmed.ncbi.nlm.nih.gov/15718317/>

Randomized Trial regarding Radiation Dosing

Zagars 2004:

<https://ascopubs.org/doi/full/10.1200/JCO.2004.05.205>

Toxicity Outcomes

PENILE CANCER

Target Volumes (Impact-Cooper et al)

<https://pubmed.ncbi.nlm.nih.gov/40180061/>

Penile Brachytherapy (Crook et al)

<https://pubmed.ncbi.nlm.nih.gov/23453681/>

Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the InPACT:

<https://pubmed.ncbi.nlm.nih.gov/40180061/>

Penile cancer: ESMOeEURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up:

<https://www.esmoopen.com/action/showPdf?pii=S2059-7029%2824%2901250-X>

Oncologic Outcomes (Surgery and Brachytherapy):

<https://pubmed.ncbi.nlm.nih.gov/33212003/>

RENAL

(TROG) 15.03 FASTRACK II:

<https://pubmed.ncbi.nlm.nih.gov/30352550/>

EAU guideline 2025 update:

<https://pubmed.ncbi.nlm.nih.gov/40118739/>

IROC 2024 update:

<https://pubmed-ncbi-nlm-nih-gov.kumc.idm.oclc.org/38423047/>

SBRT for primary RCC: IROC 5 year-outcomes:

<https://pubmed.ncbi.nlm.nih.gov/36400098/>